Tag Archives: Amneal Pharmaceuticals

Analysts’ Perspective: S&P Global (SPGI), Apollo Global Management (APO), Amneal Pharmaceuticals (AMRX)

Brokerage Firm UBS upgraded S&P Global (NYSE:SPGI) shares from Neutral to Buy rating while increasing its price target from $228 to $252.

S&P Global Inc. , together with its subsidiaries, provides ratings, benchmarks, analytics, and data to the capital and commodity markets worldwide.

*

Investment Analysts Credit Suisse upgraded Apollo Global Management, (NYSE:APO) shares from Neutral to Outperform rating while increasing its price target from $39 to $42

Apollo Global Management, LLC is a publicly owned investment manager. The firm provides its services to endowment and sovereign wealth-funds, as well as other institutional and individual investors.

*

Amneal Pharmaceuticals (NYSE:AMRX) shares were upgraded by analysts at Raymond James from Market Perform to Strong Buy rating with a price target of $13.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/